Virtus Biotech Clinical Trials ETF
14 hedge funds and large institutions have $9.72M invested in Virtus Biotech Clinical Trials ETF in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
2.75% more ownership
Funds ownership: 32.77% → 35.52% (+2.8%)
4% more capital invested
Capital invested by funds: $9.33M → $9.72M (+$385K)
7% less funds holding
Funds holding: 15 → 14 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$524K |
| 2 |
LPL Financial
San Diego,
California
|
+$352K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$227K |
| 4 |
Morgan Stanley
New York
|
+$66.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$33.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$541K |
| 2 |
Jane Street
New York
|
-$390K |
| 3 |
MPWT
MassMutual Private Wealth & Trust
Windsor,
Connecticut
|
-$7.6K |
| 4 |
GRP
Global Retirement Partners
San Rafael,
California
|
-$5K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$2.79K |
BBC Hedge Fund Activity: Q2 2019 in Review
14 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2019, worth a combined $9.72M — up 4.1% from $9.33M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BBC and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Royal Bank of Canada, adding an estimated $524K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $541K sold.
- 14 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2019, down from 15 in Q1 2019.
- Funds reported $9.72M of Virtus Biotech Clinical Trials ETF stock for Q2 2019, up 4.1% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2019 and 3 closed out, a net change of -1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2019 was Royal Bank of Canada, an estimated $524K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2019 was Susquehanna International Group, an estimated $541K sold.
Based on aggregated 13F filings for Q2 2019.